PIERIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12 USD | +2.67% |
|
-8.54% | -17.58% |
| Apr. 19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
| Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Presentation Operator MessageOperator (Operator)Good day, and welcome to our Pieris Pharmaceut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Companyâs clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.58% | 14.84M | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +2.88% | 22.19B | |
| -16.16% | 21.33B | |
| -7.22% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
- Stock Market
- Equities
- PIRS Stock
- News Pieris Pharmaceuticals, Inc.
- Transcript : Pieris Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 11, 2022
